Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy
Molecular Cancer Research - United States
doi 10.1158/1541-7786.mcr-15-0321
Full Text
Open PDFAbstract
Available in full text
Date
November 18, 2015
Authors
Publisher
American Association for Cancer Research (AACR)